Anti-gingivitis Mouthrinse

Inclusion Criteria: * Availability for the six-month duration of the clinical research study. * Good general health. * Minimum of 20 uncrowned permanent natural teeth (excluding third molars). * Initial gingivitis index of at least 1.5 as determined by the use of the Gingival Index (Löe 1967). * Initial plaque index of at least 1.5 as determined by the use of the Plaque Index (Turesky et al. 1970). * Signed Informed Consent Form. Exclusion Criteria: * Presence of orthodontic bands. * Malign tumor(s) of the soft or hard tissues of the oral cavity. * Antibiotic use any time during the one-month period prior to entry into the study. * Participation in any other clinical study or test panel within the one month prior to entry into the study. * Dental prophylaxis during the past two weeks prior to baseline examinations. * History of allergies to oral care/personal care consumer products or their ingredients. * On any prescription medicines that might interfere with the study outcome. * An existing medical condition that prohibits eating or drinking for periods up to 4 hours. * History of alcohol or drug abuse. * Self-reported pregnant or lactating subjects. * Participants who have systemic diseases that require regular systemic medication intake that may affect the gingival condition (e.g. antibiotics, phenytoin, nifedipine, cyclosporine, steroids, antiphlogistics). * Participants who require antibiotic treatments for dental appointments. * Participants with current moderate or severe chronic or aggressive periodontitis (periodontitis screening index \[PSI\] \>2 in more than 2 sextants or PSI \>3). * Subjects with caries requiring treatment (e.g., caries with cavity) or other oral diseases (including gingival hyperplasia, diseases of the oral mucosa); * Smokers or/and users of tobacco products. * Persons, who are unable to give their consent (e.g., persons who have limited legal capacity)